Fierce Pharma
NOVEMBER 30, 2023
With layoffs hitting employees on both sides of the Atlantic, Pfizer’s $3.5 billion cost-cutting spree has kicked it into high gear this month. | The company's Groton, Connecticut, research site is the latest to fall victim to job cuts as part of Pfizer's massive $3.5 billion cost-cutting mission, following layoffs across the U.S. and the U.K.
MedCity News
NOVEMBER 30, 2023
While more generative AI tools are becoming available in healthcare for diagnostics and patient communication, it is important for clinicians and healthcare staff to be aware of the security, privacy, and compliance risks when entering protected health information (PHI) into a tool like ChatGPT.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
NOVEMBER 30, 2023
The sizzling antibody-drug conjugate (ADC) field is at the center of another major life sciences deal. | The sizzling antibody-drug conjugate field is at the center of another major life sciences deal. Hoping to redeem itself following the epic Rova-T failure, AbbVie is shelling out $10.1 billion in cash to acquire ImmunoGen, maker of the ovarian cancer treatment Elahere.
MedCity News
NOVEMBER 30, 2023
With Cigna mostly focused on the commercial market and Humana mostly focused on the Medicare Advantage market, the rumored combination rumors check out, according to one industry expert.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
NOVEMBER 30, 2023
Way back in 2015 a post on the Think with Google blog made the bold claim that, for marketers, consumer intent is more powerful than demographics: “Intent beats identity. | GoodRx is a trusted, high-intent platform that helps providers and patients find what they need at the exact moment they are looking for something. Learn why intent matters more than demographics.
MedCity News
NOVEMBER 30, 2023
By revisiting practice workflows to implement more strategic habits of communication and documentation, clinicians can promote positive outcomes and mitigate practice liability risks at a time when patients maybe accessing care from myriad sources, some online.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
European Pharmaceutical Review
NOVEMBER 30, 2023
Biocon Biologics Ltd has successfully completed integration of Viatris’ biosimilar business in 31 European countries. Following the acquisition of substantially all global biosimilar business of Viatris in November 2022, and the related integration of over 70 emerging market countries in July 2023 and North America in September 2023, now that Viatris’ biosimilars operations have fully transitioned to Biocon Biologics Ltd in Europe, the company declared that this “represents another significant m
Fierce Pharma
NOVEMBER 30, 2023
Seven weeks after a federal judge dismissed (PDF) a Novo Nordisk’s lawsuit, which accu | Seven weeks after a federal judge dismissed a Novo Nordisk’s lawsuit, which accused a Florida pharmacy of selling unauthorized knockoffs of its GLP-1 Wegovy, Ozempic and Rybelsus, Novo has sued the same company. Brooksville Pharmaceuticals is the target of a refiled Novo lawsuit, this one claiming there are impurities in the company’s compounded versions of the popular weight loss treatments.
pharmaphorum
NOVEMBER 30, 2023
AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.
Fierce Pharma
NOVEMBER 30, 2023
Because of the recent Thanksgiving holiday in the U.S., we're highlighting two weeks' worth of biopharma news related to Asia. | AstraZeneca in-licensed a KRAS G12D inhibitor from China's Usynova. BeiGene bought global rights to a CDK2 inhibitor in a deal worth up to $1.3 billion. Coherus has priced the first Chinese PD-1 inhibitor to enter the U.S. market at a 20% discount to Merck's Keytruda.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
European Pharmaceutical Review
NOVEMBER 30, 2023
In a paper published in Microbiology Spectrum , researchers from Singapore have described a novel microbial contamination-detection method for T-cell cultures that can be achieved within 24 hours, therefore supporting cell therapy manufacturing. This is compared to traditional methods which take between seven to 14 days. Technology such as third-generation nanopore long-read sequencing and DNA extraction, alongside machine learning algorithms, computational analysis and optimisation, were utili
Fierce Pharma
NOVEMBER 30, 2023
As the battle between new respiratory syncytial virus (RSV) vaccines heats up, GSK is “delighted” with the progress it's made so far with Arexvy, the company's CEO Emma Walmsley has said. | As the battle between new respiratory syncytial virus vaccines heats up, GSK is “delighted” with the progress it's made so far with Arexvy, the company’s CEO Emma Walmsley said during a Reuters interview.
MedCity News
NOVEMBER 30, 2023
AbbVie announced plans to acquire Immunogen — and the biotech’s recently approved ADC treatment for ovarian cancer — for $10.1 billion in cash. The pharma giant is diving into ADCs again after a previous multibillion-dollar acquisition of a different ADC drugmaker ended up failing a few years ago.
Fierce Pharma
NOVEMBER 30, 2023
It’s critical to keep your workplace equipment clean and calibrated—especially in the realm of pharmaceutical manufacturing. Now, Dr. | It’s critical to keep your workplace equipment clean and calibrated—especially in the realm of pharmaceutical manufacturing. Now, Dr. Reddy’s failure to uphold those standards has landed the Indian drugmaker in hot water with the U.S.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
NOVEMBER 30, 2023
Alpha Sophia Founder and CEO Paul-Lukas Hoffschmidt explains how the company’s software diverges from competitors in healthcare commercial intelligence, by focusing on smaller medtech innovators.
Fierce Pharma
NOVEMBER 30, 2023
Did you know nearly 1.3 million cases of blood cancer are diagnosed worldwide each year?1 | An inside look at Sanofi’s approach to hematology R&D: Q&A with new Global Head of Oncology, Olivier Nataf.
MedCity News
NOVEMBER 30, 2023
The Walgreens Rx Savings Finder combines different third-party discount card options into one platform. It allows customers to search for a prescription, find a coupon for that prescription and text or email the coupon to themselves. They then show the coupon to a Walgreens pharmacist when they fill the prescription.
Fierce Pharma
NOVEMBER 30, 2023
Written by: Philippe Michiels, Principal Architect at Datapharm | Datapharm presents the case for standardizing digital formats of medicines information, which for too long has been characterized by unstructured data.
PharmaVoice
NOVEMBER 30, 2023
John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.
Fierce Pharma
NOVEMBER 30, 2023
As Johnson & Johnson’s top moneymaker Stelara nears its patent cliff, biosimilar makers are eager to launch their own versions of the blockbuster immunology med. | Samsung Bioepis' biosimilar, which Sandoz has agreed to commercialize, can launch on Feb. 22, 2025, pending an FDA approval. J&J has reached similar deals with other companies seeking to market their own Stelara biosimilars.
pharmaphorum
NOVEMBER 30, 2023
FDA chief scientist Namandjé Bumpus has been named as principal deputy commissioner, replacing long-serving Janet Woodcock when she steps down early next year. Bumpus is heading for the number two position at the FDA – second only to Commissioner Robert Califf who announced the appointment on X (formerly Twitter) – just over a year after she joined the agency.
European Pharmaceutical Review
NOVEMBER 30, 2023
o find out about the current trends in cell and gene therapy manufacturing, EPR spoke to Cell and Gene Therapy Catapult (CGT Catapult)’s Chief Manufacturing Officer, Stephen Ward, and Chief Business Officer, Jeanette Evans. They highlighted key data from the organisations recently published good manufacturing practice (GMP) Manufacturing Survey and Skills Demand reports, which focus particularly on the UK’s landscape.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
PharmExec
NOVEMBER 30, 2023
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare but serious and potentially fatal reaction linked to use of antiseizure medications.
Pharmaceutical Technology
NOVEMBER 30, 2023
The move is a strategic response amid challenges faced by the non-viral gene therapy sector, with several startups closing this year.
PharmaTimes
NOVEMBER 30, 2023
The new hub will unite researchers worldwide to exchange ideas and knowledge - News - PharmaTimes
Pharmaceutical Technology
NOVEMBER 30, 2023
As more cell and gene therapies get approved to treat common conditions, scaling them up will be a challenge.
PharmExec
NOVEMBER 30, 2023
The use of real-world evidence can prevent pharma companies from performing studies based on flawed data.
PharmaTimes
NOVEMBER 30, 2023
The new method successfully performs sterility assessments within 24 hours - News - PharmaTimes
Pharmaceutical Technology
NOVEMBER 30, 2023
GlobalData tracks 49 drugs in development for Gliosarcoma by 39 companies/universities/institutes. The top development phase for Gliosarcoma is phase i, with 22 drugs in that stage.
MedCity News
NOVEMBER 30, 2023
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
363 
Let's personalize your content